Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion includes Fluridil 7% treatment. Users report no side effects and convenient use, considering increasing to 10%.

User mixed RU58841 with stemoxydine, experienced no side effects. Mixing RU58841 with fluridil caused chest tightness.

Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.

The conversation is about the potential side effects of using verteporfin in conjunction with a hair transplant. Specific treatments discussed include verteporfin, a hair transplant (HT), minoxidil (Min), finasteride (Fin), and RU58841 (RU).

Fluridil may decrease the number of androgen receptors in hair follicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.

The conversation discusses hair loss treatments, specifically Verteporfin. Users also mention Minoxidil, finasteride, and RU58841.

Considering adding Low Level Laser Therapy (LLLT) to a hair loss prevention regimen; discussing the effectiveness of LLLT, and evaluating double-blind random-controlled trials that have been conducted on laser combs.

The user is using minoxidil and recently started fluridil for mild hair loss and is questioning if this treatment is sufficient without finasteride. They have finasteride available but prefer not to use it.

Verteporfin human clinical trials for hair loss may start in 2025. Additional resources and presentations are available for more information.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

Hair loss discussion mentions treatments Minoxidil, Finasteride, and RU58841. Verteporfin shows promise for scar/regrowth after 84 days.

The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.

The user experienced hair thinning from chromium and alpha lipoic acid supplements, which stopped after discontinuing them. Someone mentioned this could be telogen effluvium, a temporary condition.

The conversation discusses the appearance and testing of RU58841 powder for hair loss treatment. Users also mention side effects of RU58841 and suggest alternatives like dutasteride and minoxidil.

AltruisticBro's experience with Fluridil (Eucapil) as a hair loss treatment, and the current blood work results associated with it. They are not willing to take finasteride due to potential permanent side effects.

The conversation is about finding a source for Alfatradiol 0.1% as most available products are 0.025%. A suggestion was made to use four times the dosage of the 0.025% product.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

User creates 0.1% topical finasteride solution using Alfatradiol Avixis base. Seeks help to ensure alfatradiol base dissolves finasteride.

Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.

The user is undergoing Mesotherapy and Low-Level Laser Therapy for hair loss, with plans for multiple sessions. They are also using oral finasteride, topical minoxidil, dutasteride, and hair fibers.

The user is currently using alfatradiol and fluridil for hair loss and is considering adding low-dose topical finasteride but is concerned about potential side effects due to past mental health issues. They are seeking others' experiences with these treatments and their effectiveness.

Hair loss discussion focused on Fluridil treatment. Availability of higher concentrations questioned.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

Fluridil is considered safe with moderate effectiveness for hair loss, but its cost of €50 per month is seen as high compared to other treatments. The user is considering Pyri as a more cost-effective option and is seeking success stories about Fluridil's ability to stop hair loss without side effects.

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

The conversation is about finding an affordable and effective low level laser therapy device for hair loss, with a preference for a cap but open to a comb.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

User discusses trying Low Level Laser Therapy (LLLT) for hair loss and its high cost. Another user shares their experience combining micro needling, minoxidil, and LLLT, seeing positive results after 2 months.